| WB | 咨询技术 | Recombinant protein |
| IF | 1/20-1/50 | Recombinant protein |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Recombinant protein |
| ICC | 1/50-1/200 | Recombinant protein |
| FCM | 1/20-1/100 | Recombinant protein |
| Elisa | 咨询技术 | Recombinant protein |
| Aliases | SYNI; SYN1a; SYN1b |
| Entrez GeneID | 6853 |
| clone | 7B1D9 |
| WB Predicted band size | 74.1kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Purified recombinant fragment of human SYN1 (AA: 362-511) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CRISPR-Cas9抗体的参考文献示例(注：文献为虚拟构造，供格式参考)：
---
1. **标题**: *Development of High-Affinity Monoclonal Antibodies for CRISPR-Cas9 Detection*
**作者**: Zhang, Y. et al. (2021)
**摘要**: 本研究报道了针对SpCas9蛋白的单克隆抗体的开发，通过噬菌体展示技术筛选出高特异性抗体，成功应用于Western blot和免疫荧光检测，灵敏度达皮摩尔级别，为基因编辑效率评估提供工具。
---
2. **标题**: *Anti-Cas9 Nanobodies Neutralize Off-Target Activity in Human Cells*
**作者**: Smith, J. & Chen, F. (2020)
**摘要**: 利用骆驼源单域抗体(纳米抗体)靶向Cas9的核酸酶结构域，证明其可有效抑制非特异性DNA切割，降低CRISPR编辑的脱靶效应，为精准基因治疗提供新策略。
---
3. **标题**: *CRISPR-Cas9-Specific Antibody Engineering for In Vivo Protein Clearance*
**作者**: Lee, S. et al. (2022)
**摘要**: 开发了一种基于抗体的Cas9降解系统，通过融合抗Cas9抗体与E3泛素连接酶，实现编辑后Cas9蛋白的快速清除，减少长期毒性，提升体内应用安全性。
---
如需真实文献，建议在PubMed或Google Scholar搜索关键词：**"anti-Cas9 antibody"**, **"Cas9 monoclonal antibody"**, **"CRISPR-Cas9 detection"**。
CRISPR-Cas9 system, a revolutionary genome-editing tool derived from bacterial immune defenses, relies on the Cas9 endonuclease to target and cleave specific DNA sequences. While wild-type Cas9 enables precise edits, its activity requires tight control to minimize off-target effects. Cas9-specific antibodies, such as anti-Cas9 single-chain variable fragments (scFvs) or monoclonal antibodies (e.g., Cas9SA antibodies), have emerged as critical tools for regulating, detecting, or inhibiting Cas9 activity in research and therapeutic contexts. These antibodies are engineered to bind epitopes on Cas9. either blocking its DNA-binding domain, inhibiting nuclease function, or enabling cellular tracking via immunodetection.
Cas9SA antibodies, in particular, are designed for high specificity and affinity, often validated in applications like Western blotting, immunofluorescence, or CRISPR-Cas9 delivery monitoring. They also hold therapeutic potential—for instance, neutralizing residual Cas9 activity post-gene editing to enhance safety. Development typically involves immunizing animals with recombinant Cas9 or phage display libraries to isolate optimized binders. As CRISPR technologies advance, such antibodies contribute to improving precision in gene-editing workflows and addressing challenges like immunogenicity or off-target risks in clinical applications.
×
